AIMS: The present study aimed to assess vitamin D status and serum concentrations of pro-inflammatory cytokines IL-17, Il-23, and IL-18 in patients with chronic plaque psoriasis and their association with various demographic and clinical characteristics. METHODS: The study was conducted during the autumn/winter period on 48 patients with chronic plaque psoriasis and 48 controls. Total serum 25(OH)D level was determined with Roche Elecsys® 2010 Vitamin D total assay. Commercial ELISA kits were used for quantifying the serum levels of IL-17A, IL-18, and IL-23. RESULTS: Serum 25(OH)D had a median value of 16.95 ng/mL (IQR 10.8-23.50) for patients with psoriasis and 18.80 ng/mL (IQR 15.45-25.85) for the control group (P=0.09). A moderate negative correlation was found between PASI score and 25(OH)D levels (rs=-0.34; P=0.02). The serum levels of IL-17 (P=0.001), IL-23 (P=0.01) and IL-18 (P=0.02) were significantly higher in the patient group compared to controls. IL-17 concentrations were higher in patients with moderate to severe psoriasis compared to patients with mild psoriasis (P=0.003). No significant correlations were detected between the serum concentrations of 25(ОH)D and IL-17, IL-23, and IL-18. CONCLUSION: It was confirmed that IL-17 serum level is associated with psoriasis severity. Measurement of 25(OH)D serum concentration can be useful in patients with moderate to severe psoriasis with or without comorbidities. A direct association between 25(OH)D serum concentration and the serum concentrations of IL-17, IL-23, or IL-18 was not identified in this study.

Department of Internal Medicine and Clinical Laboratory Faculty of Medicine University Hospital Trakia University Stara Zagora Bulgaria

Department of Molecular Biology Immunology and Medical Genetics Faculty of Medicine University Hospital Trakia University Stara Zagora Bulgaria

Section of Dermatovenereology Clinic of Dermatology and Venereology Faculty of Medicine University Hospital Trakia University Stara Zagora Bulgaria

Section of Pharmacology and Clinical Pharmacology Faculty of Medicine University Hospital Trakia University Stara Zagora Bulgaria

See more in PubMed

Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol 2014;32(3):343-50. DOI

Fleming P, Kraft J, Gulliver WP, Lynde C. The relationship of obesity with the severity of psoriasis: a systematic review. J Cutan Med Surg 2015;19:450-6. DOI

Oliveira Mde F, Rocha Bde O, Durate GV. Psoriasis: Classical and emerging comorbidities. An Bras Dermatol 2015;90:9-20. DOI

Egeberg A, Mallbris L, Warren RB, Bachelez H, Gislason GH, Hansen PR, Skov L. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol 2016;175(3):487-92. DOI

Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017;76(3):377-90. DOI

Vashist S, Mahajan VK, Mehta KS, Chauhan PS, Yadav RS, Sharma SB, Sharma V, Sharma A, Chowdhary B, Kumar P.Association of psoriasis with autoimmune disorders: results of a pilot study. Indian Dermatol Online J 2020;11(5):753-9. DOI

Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009;129(7):1601-3. DOI

Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol 2009;9(10):679-91. DOI

Bugaut H, Aractingi S. Major role of the IL17/23 axis in psoriasis supports the development of new targeted therapies. Front Immunol 2021;12:621956. DOI

Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, Prinz JC.The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol 2017;31(10):1616-26. DOI

Ha HL, Wang H, Pisitkun P, Kim JC, Tassi I, Tang W, Morasso MI, Udey MC, Siebenlist U. IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc Natl Acad Sci USA 2014;111(33):E3422-E3431. DOI

Karthaus N, van Spriel AB, Looman MWG, Chen S, Spilgies LM, Lieben L, Carmeliet G, Ansems M, Adema GJ. Vitamin D controls murine and human plasmacytoid dendritic cell function. J Invest Dermatol 2014;134(5):1255-64. DOI

Tang J, Zhou R, Luger D, Zhu W, Silver PB, Grajewski RS, Su SB, Chan CC, Adorini L, Caspi RR. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol 2009;182(8):4624-32. DOI

Jeffery LE, Burke F, Mura M, Zheng Y, Qureshi OS, Hewison M, Walker LS, Lammas DA, Raza K, Sansom DM. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009;183(9):5458-67. DOI

Yamamoto E, Jørgensen TN. Immunological effects of vitamin D and their relations to autoimmunity. J Autoimmun 2019;100:107-16. DOI

Gisondi P, Rossini M, Di Cesare A, Idolazzi L, Farina S, Beltrami G, Peris K, Girolomoni G. Vitamin D status in patients with chronic plaque psoriasis. Br J Dermatol 2012;166(3):505-10. DOI

Ricceri F, Pescitelli L, Tripo L, Prignano F. Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis. J Am Acad Dermatol 2013;68(3):511-2. DOI

Mattozzi C, Paolino G, Salvi M, Macaluso L, Luci C, Morrone S, Calvieri S, Richetta AG. Peripheral blood regulatory T cell measurements correlate with serum vitamin D level in patients with psoriasis. Eur Rev Med Pharmacol Sci 2016;20(9):1675-9.

Maleki M, Nahidi Y, Azizahari S, Meibodi NT, Hadianfar A. Serum 25-OH vitamin D level in psoriatic patients and comparison with control subjects. J Cutan Med Surg 2016;20(3):207-10. DOI

Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988;124(6):869-71. DOI

Matteo & Michela Corti, 2009-2019, Psoriasis Area Severity Index (PASI) Calculator (1.7.3). 2007 Free Software Foundation. Available from: http://pasi.corti.li/

Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar NDefinition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011;303(1):1-10. DOI

WHO, Europe. A healthy lifestyle - WHO recommendations. Available from: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi

Holick, MF. Vitamin D Deficiency. N Engl J Med. 2007;357:266-81. DOI

Amrein K, Scherkl M, Hoffmann M, Neuwersch-Sommeregger S, Köstenberger M, Tmava Berisha A, Martucci G, Pilz S, Malle O. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 2020;74(11):1498-513. DOI

Orgaz-Molina J, Buendía-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J Am Acad Dermatol 2012;67(5):931-8. DOI

Filoni A, Vestita M, Congedo M, Giudice G, Tafuri S, Bonamonte D. Association between psoriasis and vitamin D: Duration of disease correlates with decreased vitamin D serum levels: An observational case-control study. Medicine (Baltimore). 2018 Jun;97(25):e11185. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023690/ DOI

El-Moaty Zaher HA, El-Komy MHM, Hegazy RA, Mohamed El Khashab HA, Ahmed HH. Assessment of interleukin-17 and vitamin D serum levels in psoriatic patients. J Am Acad Dermatol 2013;69(5):840-2. DOI

Zuchi MF, Azevedo Pde O, Tanaka AA, Schmitt JV, Martins LE. Serum levels of 25-hydroxy vitamin D in psoriatic patients. An Bras Dermatol 2015;90(3):430-2. DOI

Wilson PB. Serum 25-hydroxyvitamin D status in individuals with psoriasis in the general population. Endocrine 2013;44(2):537-9. DOI

Bergler-Czop B, Brzezińska-Wcisło L. Serum vitamin D level - the effect on the clinical course of psoriasis. Postepy Dermatol Alergol 2016;33(6):445-9. DOI

Lee YH, Song GG. Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: a meta-analysis. Clin Exp Dermatol 2018;43(5):529-35. DOI

Tajjour R, Baddour R, Redwan F, Hassan F. The Relationship between Psoriasis and Serum Levels of Vitamin D. J Adv Med Med Res 2018;26(3):1-12. DOI

Chandra R, Roesyanto-Mahadi ID, Yosi A. Pilot study: immunohistochemistry expressions of vitamin D receptor associated with severity of disease in psoriasis patients. Int J Dermatol 2020;59(9):1092-7. DOI

Pitukweerakul S, Thavaraputta S, Prachuapthunyachart S, Karnchanasorn R. Hypovitaminosis D is associated with psoriasis: a systematic review and meta-analysis. Kans J Med 2019;12(4):103-8. DOI

Brożyna AA, Slominski RM, Nedoszytko B, Zmijewski MA, Slominski AT. Vitamin D signaling in psoriasis: pathogenesis and therapy. Int J Mol Sci 2022;23(15):8575. DOI

Amital H, Szekanecz Z, Szücs G, Dankó K, Nagy E, Csépány T, Kiss E, Rovensky J, Tuchynova A, Kozakova D, Doria A, Corocher N, Agmon-Levin N, Barak V, Orbach H, Zandman-Goddard G, Shoenfeld Y. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010;69(6):1155-7. DOI

Zold E, Barta Z, Bodolay E. Vitamin D deficiency and connective tissue disease. Vitam Horm 2011;86:261-86. DOI

Melguizo-Rodríguez L, Costela-Ruiz VJ, García-Recio E, De Luna-Bertos E, Ruiz C, Illescas-Montes R. Role of Vitamin D in the Metabolic Syndrome. Nutrients 2021;13(3):830. DOI

Furue K, Ito T, Tsuji G, Kadono T, Nakahara T, Furue M. Autoimmunity and autoimmune co-morbidities in psoriasis. Immunology 2018;154(1):21-7. DOI

Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013;68(4):654-62. DOI

Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E. Psoriasis and Metabolic Syndrome-scientific evidence and therapeutic implications. J Med Life 2014;7(4):468-71.

Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8(9):950-7. DOI

Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol 2017;49:1-8. DOI

Pirowska M, Obtułowicz A, Lipko-Godlewska S, Goździalska A, Podolec K, Wojas-Pelc A. The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. Postepy Dermatol Alergol 2018;35(4):360-6. DOI

Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R, An J, Ma H. Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget 2018;9(1):1266-78. DOI

Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JGIncreased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199(1):125-30. DOI

El Hadidi H, Grace BDM, Gheita T, Shaker O. Involvement of IL-23 in psoriasis and psoriatic arthritis patients; possible role in pathogenesis. J Egypt wom Dermatol Soc 2008;5:70-5.

Łukasik Z, Gracey E, Venken K, Ritchlin C, Elewaut D. Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints. Rheumatology (Oxford) 2021;60(Suppl 4):iv16-iv27. PubMed DOI

Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG. Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb) 2021;11(2):385-400. DOI

Brembilla NC, Senra L, Boehncke WH. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol 2018;9:1682. doi:10.3389/fimmu.2018.01682 PubMed DOI

Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized controlled trial. J Clin Immunol 2009;29(2):210-4. DOI

Bajaj S, Gautam RK, Khurana A, Arora P, Sharma N. Effect of narrow band ultraviolet B phototherapy on T helper 17 cell specific cytokines (interleukins-17, 22 and 23) in psoriasis vulgaris. J Dermatolog Treat 2017;28(1):14-7. PubMed DOI

Sobhan M, Ghasemi Basir HR, Seif Rabiee MA, Shadfar F. Serum level of interleukin-17 in patients with psoriasis. Immunopathol Persa 2022;x(x):e29269. doi:10.34172/ipp.2022.29269 DOI

Michalak-Stoma A, Bartosińska J, Kowal M, Raczkiewicz D, Krasowska D, Chodorowska G. IL-17A in the Psoriatic Patients' Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity. Mediators Inflamm 2020;2020:7420823. doi:10.1155/2020/7420823 PubMed DOI

Kyriakou A, Patsatsi A, Vyzantiadis TA, Sotiriadis D. Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J Immunol Res 2014;2014:467541. doi:10.1155/2014/467541 PubMed DOI

Shah SR, Shaikh SB, Bhandary YP, Yassir S, Shenoy MM. Relevance of inflammatory cytokine mRNA expression of tumor necrosis factor-alpha (TNF α), interleukin 17A (IL 17A), and interleukin 6 (IL 6) in Indian patients with psoriasis. Indian Dermatol Online J 2022;13(2):229-33. DOI

Fitz L, Zhang W, Soderstrom C, Fraser S, Lee J, Quazi A, Wolk R, Mebus CA, Valdez H, Berstein G. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis. Clin Exp Dermatol 2018;43(7):790-7. PubMed DOI

Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O, Perret C, Münzel T, Rupprecht HJ, Lackner K, Cambien F, Blankenberg S. AtheroGene Investigators. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005;112(5):643-50. PubMed DOI

Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30. DOI

Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schönbeck U, Khera A, McGuire DK, Vega GL, Grundy S, Libby P, de Lemos JA.Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 2007;27(9):2043-9. DOI

Su W, Zhao Y, Wei Y, Zhang X, Ji J, Yang S. Exploring the pathogenesis of psoriasis complicated with atherosclerosis via microarray data analysis. Front Immunol 2021;12:667690. doi:10.3389/fimmu.2021.667690 PubMed DOI

von Stebut E, Boehncke WH, Ghoreschi K, Gori T, Kaya Z, Thaci D, Schäffler A.IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Front Immunol 2020;10:3096. doi:10.3389/fimmu.2019.03096 PubMed DOI

Pharmacotherapy of arterial hypertension in patients with psoriasis